Amarin Says Supplement Cos. Can't Tout Its Omega-3 Trial
By Dani Kass ( October 30, 2018, 6:52 PM EDT) -- Amarin Pharma Inc. has accused two supplement makers in California federal court of undercutting the reputation of its U.S. Food and Drug Administration-approved medication Vascepa by relying on its clinical trial to prove that their own omega-3 products have cardiovascular benefits....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.